1262P - Distinct spread of EGFR mutated pulmonary adenocarcinomas

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Cytotoxic agents
Non-small-cell lung cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Therapy
Biological therapy
Presenter Dong-Yeop Shin
Authors D. Shin1, S.Y. Kwon2, C.H. Kim3, S.H. Yang3, I.I. Na3
  • 1Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 139-706 - Seoul/KR
  • 2Hospice And Palliative Care Team, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 139-706 - Seoul/KR
  • 3Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 139-706 - Seoul/KR

Abstract

Introduction

Our aim in this study was to explore the potential association of epidermal growth factor receptor (EGFR) with characteristics of tumor spread in patients with pulmonary adenocarcinoma. Clinical implication of EGFR mutational status on brain metastasis was also evaluated in surgically treated patients.

Methods

We analyzed clinical data on 317 patients who were tested for EGFR mutation and who underwent brain MRI at diagnosis between October 2005 and December 2011. The relationship between EGFR mutation status and clinical factors were analyzed. Initial metastatic disease was stratified according to brain metastases and their association with EGFR mutations was evaluated using multinomial logistic regression.

Results

Of the 317 patients, 139 patients (43.85%) harbored EGFR mutations. EGFR mutations was more commonly found in patients with early nodal stage (71.9 % versus 28.1%, adjusted odds ratio [OR] = 1.90, p = 0.030) and distant metastases (54.0% versus 46.0%, adjusted OR = 2.05, p = 0.011). Further analysis showed that EGFR mutations were more likely to be detected in brain metastases (64.7% versus 35.3%, p = 0.005), whereas their association with noncranial metastases was not significant (55.4% versus 44.6%, p = 0.960). In addition, survival analysis of 133 patients treated with surgical resection showed that EGFR mutation status was a poor prognostic factor for brain metastasis (HR = 5.94, 95% CI = 1.08-16.28, p = 0.039) after adjustment of pathologic N stage.

Conclusions

In this study, EGFR mutation status was significantly associated with early nodal and distant metastasis, in the patients with pulmonary adenocarcinoma. The current study also suggests the preference of brain metastases in mutant EGFR tumors at initial presentation and after curative resection.

Disclosure

All authors have declared no conflicts of interest.